Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Filings indexed 1,071 across all filing types
Latest filing 2025-09-04 Capital/Financing Update
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Announces Pricing of Up To $18 Million Public Offering
Capital/Financing Update Classification · 98% confidence The document is a short regulatory filing (under 2,100 characters) from the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on Purple Biotech Announces Pricing of Up To $18 Million Public Offering' and provides a PDF filename. According to the 'Menu vs Meal' rule, since this is a short announcement of a report/offering rather than the full financial report itself, it is classified as a Report Publication Announcement (RPA).
2025-09-04 English
Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the U.S. Securities and Exchange Commission by Purple Biotech Ltd. A Form 6-K is used by foreign private issuers to report material information that is required to be made public in their home jurisdiction or provided to shareholders. The content of this specific filing is a press release announcing new research data regarding the company's CAPTN-3 platform. Since this is a standard regulatory filing used to disseminate corporate news (a press release) to the SEC, it falls under the 'Regulatory Filings' category.
2025-09-04 English
Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing from Purple Biotech Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' followed by the title of a press release/report ('Purple Biotech Announces New Data...'). Per the 'Menu vs Meal' rule, since this is a short announcement document that serves to notify the public of an attached report, it is classified as a Report Publication Announcement (RPA).
2025-09-04 English
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings Classification · 100% confidence The document is a press release issued by Purple Biotech Ltd. announcing new preclinical data for its CAPTN-3 tri-specific antibody platform (IM1240). It details scientific findings from a collaboration with the Icahn School of Medicine at Mount Sinai. As this is a corporate announcement regarding research and development progress rather than a formal financial report, a regulatory filing, or a shareholder meeting document, it falls under the category of general regulatory announcements/press releases.
2025-09-04 English
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 2,100 characters) submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' followed by a title regarding new data for a clinical trial (CAPTN-3). Per the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-09-04 English
Purple Biotech Expands CAPTN-3 Portfolio-PR
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (under 2,100 characters) from Purple Biotech Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Purple Biotech Expands CAPTN-3 Portfolio' and provides a filename 'PurpleBioTech-CAPTN3_isa.pdf'. Following the 'Menu vs Meal' rule, since this is a short announcement notifying the public of an attached report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-09-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.